The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis

Savino Sciascia; Rohan Willis; Vittorio Pengo; Steve Krilis; Danieli Andrade; Maria G Tektonidou; Amaia Ugarte; Cecilia Chighizola; D Ware Branch; Roger A Levy; Cecilia Nalli; Paul R Fortin; Michelle Petri; Esther Rodriguez; Ignasi Rodriguez-Pinto; Tatsuya Atsumi; Iana Nascimento; Renata Rosa; Alessandra Banzato; Doruk Erkan; Hannah Cohen; Maria Efthymiou; Ian Mackie; Maria Laura Bertolaccini; APS ACTION

doi:10.1016/j.thromres.2019.01.010

The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis

Thromb Res. 2019 Mar:175:32-36. doi: 10.1016/j.thromres.2019.01.010. Epub 2019 Jan 18.

Authors

Savino Sciascia¹, Rohan Willis², Vittorio Pengo³, Steve Krilis⁴, Danieli Andrade⁵, Maria G Tektonidou⁶, Amaia Ugarte⁷, Cecilia Chighizola⁸, D Ware Branch⁹, Roger A Levy¹⁰, Cecilia Nalli¹¹, Paul R Fortin¹², Michelle Petri¹³, Esther Rodriguez¹⁴, Ignasi Rodriguez-Pinto¹⁵, Tatsuya Atsumi¹⁶, Iana Nascimento⁵, Renata Rosa⁵, Alessandra Banzato³, Doruk Erkan¹⁷, Hannah Cohen¹⁸, Maria Efthymiou¹⁹, Ian Mackie¹⁹, Maria Laura Bertolaccini²⁰; APS ACTION

Affiliations

¹ Center of Research of Immunopathology and Rare Diseases, University of Turin, Italy. Electronic address: savino.sciascia@unito.it.
² Antiphospholipid Standardization Laboratory, Department of Internal Medicine, Rheumatology Division, University of Texas Medical Branch, Galveston, TX, USA.
³ Clinical Cardiology, Thrombosis Center, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy.
⁴ Department of Infectious Diseases, Immunology and Sexual Health, St George Hospital, Sydney, Australia.
⁵ Division of Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
⁶ University of Athens, Athens, Greece.
⁷ Hospital Universitario Cruces Bizkaia, Spain.
⁸ University of Milan, Milan, Italy.
⁹ University of Utah and Intermountain Healthcare, Salt Lake City, UT, USA.
¹⁰ State University of Rio de Janeiro, Rio de Janeiro, Brazil.
¹¹ Department of Clinical and Experimental Science, University of Brescia, Brescia, Italy.
¹² CHU de Quebec - Universite Laval, Quebec, Canada.
¹³ Johns Hopkins University, Baltimore, MD, USA.
¹⁴ Hospital Universitario 12 de Octubre, Madrid, Spain.
¹⁵ Department of Autoimmune Diseases, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain.
¹⁶ Hokkaido University Hospital, Sapporo, Japan.
¹⁷ Barbara Volcker Center for Women and Rheumatic Diseases, Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, USA.
¹⁸ Haemostasis Research Unit, Department of Haematology, University College London, London, UK; Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK.
¹⁹ Haemostasis Research Unit, Department of Haematology, University College London, London, UK.
²⁰ Academic Department of Vascular Surgery, Cardiovascular School of Medicine & Sciences, King's College London, UK.

PMID: 30685523
DOI: 10.1016/j.thromres.2019.01.010

Abstract

Background: The APS ACTION International Clinical Database and Repository includes a secure web-based data capture system storing patient information including demographics, antiphospholipid antibodies (aPL)-related medical history, and aPL tests. Despite efforts at harmonization, inter-assay variability remains a problem in aPL testing. As a clinical repository open to researchers, ensuring comparability between assays and consistency in results between APS ACTION laboratories is essential to the validity of studies emerging from this network.

Objective: To assess the level of agreement between an aPL-registry inclusion and core laboratory (core lab) anticardiolipin antibody (aCL) and anti-β₂-glycoprotein-I antibody (aβ₂GPI) ELISA testing results.

Methods: Patients are recruited from 25 international centers based on positive aPL tests at inclusion. All samples are retested at the corresponding national APS ACTION core lab to confirm aPL positivity based on standard validated protocols. We analysed the categorical agreement, degree of linear association, and correlation between inclusion (local laboratory) and core lab aPL tests. Samples were included in this study only if results of aPL testing with ELISA at baseline were available.

Results: 497 registry samples underwent confirmatory aPL tests. Categorical agreement between the inclusion and core lab values, as expressed by Cohen's kappa coefficients, ranged between 0.61 and 0.80 (as substantial agreement). The correlation between quantitative results in the aCL and aβ₂GPI was better for IgM and IgA compared to IgG (Spearman rho 0.789 and 0.666 vs. 0.600 for aCL and rho 0.892 and 0.744 vs. 0.432 for aβ₂GPI).

Conclusions: The results of inclusion for aCL and aβ₂GPI tests used for recruitment into the registry were in agreement to the results obtained by the APS ACTION core laboratories; aCL and aβ₂GPI results showed very good categorical agreement. This agreement increased when considering high titer (>40 units) samples. APS ACTION is a reliable and useful research resource for APS.

Keywords: Anti-β(2)-glycoprotein I; Anticardiolipin; Antiphospholipid antibodies,; Thrombosis; antiphospholipid syndrome,; miscarriages,; reproducibility.

Publication types

Multicenter Study

MeSH terms

Antibodies, Antiphospholipid / immunology*
Antiphospholipid Syndrome / immunology*
Databases, Factual
Enzyme-Linked Immunosorbent Assay / methods*
Female
Humans
Male

Substances

Antibodies, Antiphospholipid